NC
AMED

Nicholas Company’s Amedisys AMED Stock Holding History

Nicholas Company’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-32,910
Closed -$3.24M – 217
2025
Q2 		$3.24M Sell
32,910
-41,377
-56% -$3.91M 0.05% 210
2025
Q1 		$6.88M Buy
74,287
+35
+0% +$3.23K 0.12% 161
2024
Q4 		$6.74M Hold
74,252
– – 0.11% 172
2024
Q3 		$7.17M Hold
74,252
– – 0.12% 166
2024
Q2 		$6.82M Sell
74,252
-35
-0% -$3.25K 0.11% 165
2024
Q1 		$6.85M Hold
74,287
– – 0.11% 168
2023
Q4 		$7.06M Hold
74,287
– – 0.13% 158
2023
Q3 		$6.94M Hold
74,287
– – 0.14% 143
2023
Q2 		$6.79M Buy
74,287
+14,045
+23% +$1.15M 0.13% 160
2023
Q1 		$4.43M Hold
60,242
– – 0.09% 196
2022
Q4 		$5.03M Buy
60,242
+7,485
+14% +$675K 0.11% 187
2022
Q3 		$5.11M Buy
52,757
+22,645
+75% +$2.7M 0.12% 185
2022
Q2 		$3.17M Buy
+30,112
New +$3.85M 0.07% 215

Other funds holding AMED

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
MCI
MRP Capital Investments Alpharetta, Georgia $115M AUM 48.08% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Nicholas Company's AMED Position: Q3 2025 in Review

Nicholas Company sold out of Amedisys (AMED) in Q3 2025, closing a stake of 32,910 shares — an estimated $3.24M sold.

Nicholas Company first reported a position in AMED in Q2 2022 and held it in 13 quarters. The position peaked at $7.17M in Q3 2024. 4 funds tracked by Wall St. Rank hold AMED as of Q3 2025.

  • Nicholas Company reported no remaining Amedisys position as of Q3 2025 after selling out during the quarter.
  • Nicholas Company sold 32,910 Amedisys shares in Q3 2025, an estimated $3.24M.
  • Nicholas Company first reported a position in Amedisys in Q2 2022 and held it in 13 quarters.
  • Nicholas Company's Amedisys position peaked at $7.17M in Q3 2024.
  • 4 funds tracked by Wall St. Rank held Amedisys as of Q3 2025.

Based on Nicholas Company's 13F filing for Q3 2025, filed 12 Nov 2025.